
Onconius
@onconius
La página donde podrás estar al día en Oncología de una forma crítica
The page where you can stay up to date in Oncology in a critical way.
ID: 1664654648400048128
http://onconius.com 02-06-2023 15:26:35
52 Tweet
31 Followers
36 Following





The latest update of the MONALEESA-3 trial is just published on BreastCancerResearch, reporting the longest OS to date for 1L patients in a phase 3 ABC trial (median OS with fulvestrant + ribociclib: 67.6 months). …ast-cancer-research.biomedcentral.com/counter/pdf/10…


Adjuvant alectinib improves DFS vs chemotherapy in pts after resection of a stage IB to IIIA ALK+ NSCLC . Results of phase III trial ALINA spkl.io/60134l8TL. Impact on OS, rate of cross over and brain mets incidence to be followed. Likely to be a new SoC. ALK Positive



Los anticuerpos conjugados asociados a inmunoterapia llegan a la primera línea de tratamiento en cáncer de vejiga avanzado #emfortumabvedotin #pembrolizumab Astellas Europe Astellas Pharma US MSD España @msd onconius.com/blog-1/los-ant…

Systematic review of TKI efficacy in NSCLC harboring uncommon EGFR mutations JTO & JTO CRR: - 1836pts, 38 studies - G719X, S768I, E709X, L747X; compound mtns; & PACC mtns: best ORR to 2nd-gen TKIs - L861Q best ORR to 3rd gen TKI Alfredo Addeo MD OncoAlert #LCSM jto.org/article/S1556-…


#Nivolumab adyuvante mejora la supervivencia global en pacientes con cáncer de vejiga: resultados del estudio CheckMate 274 #EAU24 Matt Galsky onconius.com/blog-1/nivolum…

Adjuvant #Nivolumab Improves Overall Survival in #BladderCancer #checkmate274 #EAU24 Bristol Myers Squibb Bristol Myers Squibb España & Portugal onconius.com/blog-1/nivolum…


